SHERIDAN, WYOMING – July 25, 2025 – Roche has reported strong momentum in the first half of 2025, achieving 7% sales growth at constant exchange rates (CER) and a 23% increase in IFRS net income, driven by high demand for innovative pharmaceutical treatments and effective cost control measures.
Strong Performance in Pharmaceuticals Drives Growth
Roche’s Pharmaceuticals Division delivered a standout performance, with sales rising 10% (CER) to CHF 24.0 billion. This increase was propelled by robust demand for key therapies including Phesgo, Xolair, Hemlibra, Vabysmo, and Ocrevus, which together contributed CHF 10.6 billion in sales — a CHF 1.7 billion increase over the same period last year.
The U.S. market posted a 10% sales increase, while growth in Europe, Japan, and the international region further solidified Roche’s global footprint. Notably, Phesgo saw rapid adoption across multiple regions, particularly in Japan and emerging markets.
Diagnostics Division Maintains Stability Despite External Pressures
While sales in the Diagnostics Division held flat at CER (down 3% in CHF), strong demand for pathology solutions and blood screening tests helped offset headwinds from healthcare pricing reforms in China. Performance in Europe, the Middle East, and Africa (up 5%) and North America (up 6%) highlighted the resilience of Roche’s diagnostic portfolio.
Pipeline Advances Reinforce Strategic Positioning
CEO Thomas Schinecker emphasized the company’s continued innovation leadership: “Roche’s strong growth momentum continued in the second quarter, driven by the strong growth of 11% at constant exchange rates in our Pharmaceuticals Division. We received numerous important approvals and reported positive data in disease areas with high unmet medical need.”
Key pipeline milestones included:
- Regulatory approvals:
- Susvimo approved in the U.S. for diabetic retinopathy.
- Itovebi and Evrysdi tablet approved in the EU for breast cancer and spinal muscular atrophy, respectively.
- Phesgo received a CHMP recommendation for at-home use in the EU.
- New data and pivotal trials:
- NXT007 showed promise in haemophilia A with zero bleeds requiring treatment in high-dose groups.
- Prasinezumab progressed to phase III for early Parkinson’s disease.
- Lunsumio + Polivy combination demonstrated significantly prolonged remission in lymphoma patients.
- Tecentriq + lurbinectedin combo showed a 46% risk reduction in disease progression for small cell lung cancer.
- Innovation in diagnostics:
- Launch of the Elecsys PRO-C3 test for liver fibrosis assessment.
- FDA approval of the VENTANA MET (SP44) assay and Breakthrough Device Designation for the AI-driven VENTANA TROP2 assay.
- A new strategic collaboration with Broad Clinical Labs to accelerate adoption of SBX whole-genome sequencing for newborn diagnostics.
Operational and Financial Highlights
- Group sales reached CHF 30.9 billion, with core operating profit up 11% to CHF 12.0 billion.
- Core earnings per share rose by 12%, while IFRS net income surged 23% to CHF 7.8 billion.
- Roche reconfirmed its 2025 outlook, anticipating mid-single-digit sales growth and high-single-digit core EPS growth at CER.
Strategic Resilience Amid Market Challenges
Despite headwinds from biosimilar erosion and pricing reforms, Roche’s innovation-led portfolio and strategic global expansion continue to drive resilient growth. The company’s proactive investments in next-generation therapies and diagnostics strengthen its long-term positioning.
Schinecker concluded, “We are confident in our continued strong momentum and resilience of our business due to our innovative on-market portfolio and pipeline. Based on these strong results, we confirm our full-year outlook.”
Learn more at www.roche.com